The anti-tumor activity of 5a-HSA was then evaluated in other syngeneic subcutaneous tumor models based on TS/A mammary adenocarcinoma, WEHI-164 fibrosarcoma, and TRAMP-C2 prostate carcinoma. This evidence concerns the gene ALB and prostate carcinoma.